Compare Amylx Pharmaceuticals Inc (AMLX) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Marriott International Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.84 (market cap $2.64B), while Marriott International Inc trades at $355.74 (market cap $91.14B). The key difference: Marriott International Inc is far larger — about 34.5× Amylx Pharmaceuticals Inc's market cap, and Marriott International Inc pays a 0.84% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MAR | |
|---|---|---|
Market Cap | $2.64B | $91.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $402.54 |
52-Week Low | $7.82 | $259.04 |
Enterprise Value | $2.39B | $108.45B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Marriott International (MAR) trades at $356.31, up 2.26% today, with a bearish technical signal from moving averages. Recent Q2 2026 earnings beat estimates with EPS of $3.19 versus $3.08 expected, driven by strong fee revenue growth. The company raised its 2026 outlook, supported by a record pipeline and AI-powered booking tools, though valuation remains elevated with a P/E of 36.18.
Outlook is mixed: analyst consensus targets $387.31 (8.7% upside) with 44% buy ratings, but high debt and Middle East weakness pose risks. The stock offers growth via fee-based model and dividends, but requires monitoring of RevPAR trends and macroeconomic pressures for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
